A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Condition: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers · Sponsor: Amgen
About this study
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (77)
| Comprehensive Blood and Cancer Center | Bakersfield, California, United States | — |
| City of Hope National Medical Center | Duarte, California, United States | — |
| City of Hope Orange County Lennar Foundation Cancer Center | Duarte, California, United States | — |
| University of California San Diego Moores Cancer Center | La Jolla, California, United States | — |
| Translational Research in Oncology US Inc, Trio Central Pharmacy | Los Angeles, California, United States | — |
| University of California Los Angeles | Santa Monica, California, United States | — |
| Rocky Mountain Cancer Centers | Aurora, Colorado, United States | — |
| Hartford Hospital | Hartford, Connecticut, United States | — |
| Yale University | New Haven, Connecticut, United States | — |
| Norwalk Hospital | Norwalk, Connecticut, United States | — |
| University of Chicago | Chicago, Illinois, United States | — |
| Indiana University | Indianapolis, Indiana, United States | — |
+ 65 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06360354